人血清中舍曲林、度洛西汀、氟伏沙明、氟西汀和去甲氟西汀的LC-MS/MS方法建立及临床应用

doi:10.11669/cpj.2020.24.007

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (2401 KB) HTML (0 KB)
输出: BibTeX | EndNote (RIS)

摘要目的建立人血清中舍曲林、度洛西汀、氟伏沙明、氟西汀和去甲氟西汀浓度同时测定的LC-MS/MS方法,实现临床样本的治疗药物监测。方法以N-甲基氟西汀和N-甲基度洛西汀为内标,用甲醇-乙腈(1∶1,V∶V)混合溶剂沉淀蛋白;使用ES Sonoma C₁₈(2)色谱柱(2.1 mm×50 mm,3 μm),以0.2%乙腈和50%甲醇水溶液(含6 mmol·L^-1乙酸铵)为流动相,梯度洗脱;使用三重四级杆质谱进行质量分析,采用电喷雾离子源,在正离子模式下以MRM的扫描模式进行定量分析。结果所建方法经验证,空白基质对分析物和内标无干扰,注射完高浓度样品后各分析物和内标均无残留,基质效应符合文件要求(内标归一化的基质因子变异系数CV%＜15%),处理后的样品24 h内分析稳定、未处理样本4 ℃冰箱存放1周稳定,舍曲林、度洛西汀、氟伏沙明、氟西汀及去甲氟西汀分别在9.22~295.16、10.80~345.60、8.10~259.12、10.11~323.54及5.90~188.70 ng·mL^-1内均具有良好的线性关系,r²＞0.99,方法的准确度高、精密度好。结论该方法的样本处理简单,样本分析时间短,可实现大量临床样本的快速分析,已成功应用于临床服用舍曲林、度洛西汀、氟伏沙明、或氟西汀的患者血药浓度监测。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	金靖谊
	任方龙
	郭庆合

关键词 ：舍曲林, 度洛西汀, 氟伏沙明, 氟西汀, 去甲氟西汀, 高效液相-串联质谱法, 治疗药物监测

Abstract：OBJECTIVE To develop a simple and reliable liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for therapeutic drug monitoring (TDM) of sertraline, duloxetine, fluvoxamine, fluoxetine and norfluoxetine in serum. METHODS These analytes were extracted by protein precipitation using N-methyl fluoxetine and N-methyl duloxetine as internal standard. The separation was achieved on ES Sonoma C₁₈(2) column (2.1 mm×50 mm, 3 μm) with gradient eluted program using 0.2% formic acid acetonitrile and 50% methanol-water with 6 mmol·L^-1ammonium acetate as mobile phase. API 4000 triple quadrupole system equipped with an electrospray ionization ion-trap source (ESI) was used for monitoring the analytes and which was operated in the positive ion mode. Analytes were detected in the multiple reaction monitoring (MRM) mode. RESULTS The linear calibration curve of sertraline, duloxetine, fluvoxamine, fluoxetine and norfluoxetine were obtained in the concentration range of 9.22-295.16 (r²=0.997 4), 10.80-345.60 (r²=0.995 5), 8.10-259.12 (r²=0.995 2), 10.11-323.54 (r²=0.996 7), 5.90-188.70 (r²=0.995 7) ng·mL^-1, respectively. The accuracy of intra-batch and inter-batch assays was between 93.44% and 106.20% and the precision CV% was less than 10.00%. The selectivity, matrix effect and carry-over meet the requirements. The raw samples could stay stable for seven days in 4 ℃ condition, and post-preparative stability was validated for 24 h in room temperature and meet the requirement. CONCLUSION A simple and reliable LC-MS/MS method is established and validated. And this method has already been used to monitor the serum concentration of sertraline, duloxetine, fluvoxamine, fluoxetine and norfluoxetine.

Key words： sertraline duloxetine fluvoxamine fluoxetine norfluoxetine LC-MS/MS TDM

收稿日期: 2020-06-22

PACS:	R969.1
	R917

基金资助:河南省中医管理局国家中医临床研究基地科研专项项目资助(2018JDZX043)

通讯作者: * 郭庆合,男,硕士,副教授研究方向:微生物 Tel: 13523258255 E-mail: 119867068@qq.com

作者简介: 金靖谊,女,硕士,药师研究方向:临床药学

引用本文:

金靖谊, 任方龙, 郭庆合. 人血清中舍曲林、度洛西汀、氟伏沙明、氟西汀和去甲氟西汀的LC-MS/MS方法建立及临床应用[J]. 中国药学杂志, 2020, 55(24): 2036-2043. JIN Jing-yi, REN Fang-long, GUO Qing-he. Development and Validation of a LC-MS/MS Assay for Therapeutic Drug Monitoring of Sertraline, Duloxetine, Fluvoxamine, Fluoxetine and Norfluoxetine in Serum. Chinese Pharmaceutical Journal, 2020, 55(24): 2036-2043.

链接本文:

http://journal11.magtechjournal.com/Jwk_zgyxzz/CN/10.11669/cpj.2020.24.007 或 http://journal11.magtechjournal.com/Jwk_zgyxzz/CN/Y2020/V55/I24/2036

[1]	WILLE S M, COOREMAN S G, NEELS H M, et al. Relevant issues in the monitoring and the toxicology of antidepressants [J]. Crit Rev Clin Lab Sci, 2008, 45(1):25-89.
[2]	KRUITHOF M K, BRUINS N A, VAN ROON E N. Coma after overdose with duloxetine [J]. Ann Pharmacother, 2011, 45(1):e5.
[3]	REN L N. The effect of duloxetine concentration on the core symptoms and somatic symptoms of depression [D]. Lanzhou: Lanzhou University, 2018.
[4]	KASPER S, DOTSCH M, KICK H, et al. Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects [J]. Eur Neuropsychopharmacol, 1993, 3(1):13-21.
[5]	LI C R, CHEN X Y, CHENG Y Q, et al. The clinical research progress in serum concentration of novel antidepressants[J]. J Psych, 2014, 27(2):153-156.
[6]	YUAN J, JIANG W S, LIU Y, et al. Progress in the study of gender heterogeneity in pharmacodynamics of antidepressants [J]. Chin J Mod Appl Pharm (中国现代应用药学), 2019, 36(11):1443-1447.
[7]	KNADLER M P, LOBO E, CHAPPELL J, et al. Duloxetine: clinical pharmacokinetics and drug interactions [J]. Clin Pharmacokinet, 2011, 50(5):281-294.
[8]	KATOH Y, UCHIDA S, KAWAI M, et al. Effects of cigarette smoking and cytochrome p450 2d6 genotype on fluvoxamine concentration in plasma of japanese patients [J]. Biol Pharm Bull, 2010, 33(2):285-288.
[9]	LLERENA A, DORADO P, BERECZ R, et al. Effect of cyp2d6 and cyp2c9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions [J]. Eur J Clin Pharmacol, 2004, 59(12):869-873.
[10]	SCORDO M G, SPINA E, DAHL M L, et al. Influence of cyp2c9, 2c19 and 2d6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine [J]. Basic Clin Pharmacol Toxicol, 2005, 97(5):296-301.
[11]	RASMUSSEN B B, BROSEN K. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? [J]. Ther Drug Monit, 2000, 22(2):143-154.
[12]	WANG J J, YAO Q, HUANG H, et al. Duloxetine concentration determination in human plasma with UFLC-MS/MS and applied for therapeutic drug monitoring [J]. Chin J Mod Appl Pharm(中国现代应用药学), 2019, 36(8):951-955.
[13]	KATOH Y, UCHIDA S, KAWAI M, et al. Onset of clinical effects and plasma concentration of fluvoxamine in Japanese patients [J]. Biol Pharm Bull, 2010, 33(12):1999-2002.
[14]	SUZUKI Y, FUKUI N, SAWAMURA K, et al. Concentration-response relationship for fluvoxamine using remission as an endpoint: a receiver operating characteristics curve analysis in major depression [J]. J Clin Psychopharmacol, 2008, 28(3):325-328.
[15]	JIANG P, NIE S C. Monitoring of the serum concentration of fluoxetine for depression and analysis of its clinical application [J]. Shanghai Med Pharm J(上海医药), 2015, 36(11):33-34,53.
[16]	DU W W. Research progress in therapeutic drug monitoring of fluoxetine [C]. //Anthology of the 4th National Annual Meeting of Therapeutic Drug Monitoring, 2014:121-122.
[17]	HENDSET M, HASLEMO T, RUDBERG I, et al. The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs [J]. Pharmacopsychiatry, 2006, 39(4):121-127.
[18]	BAUMANN P, HIEMKE C, ULRICH S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry [J]. Pharmacopsychiatry, 2004, 37(6):243-265.
[19]	HIEMKE C, BAUMANN P, BERGEMANN N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011 [J]. Pharmacopsychiatry, 2011, 44(6):195-235.
[20]	HIEMKE C, BERGEMANN N, CLEMENT H W, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017 [J]. Pharmacopsychiatry, 2018, 51(1-2):9-62.
[21]	CHINESE SOCIETY OF LABORATORY MEDICINE. The suggestion on development and management of laboratory developed tests in chinese medical laboratories[J]. Chin J Lab Med(中华检验医学杂志), 2017, 40(3):162-164.
[22]	LI S, ZHANG Q, ZHANG S, et al. Survey on the development of therapeutic drug monitoring in Chinese hospitals in 2018 [J]. Chin Pharm J (中国药学杂志), 2019, 54(24):2087-2092.
[23]	Ch.P (2015). Vol Ⅳ(中国药典2015年版. 四部) [S]. 2015: 648.
[24]	LI Y, REN F L, MA S J, et al. Determination of plasma concentration of risperidone and 9-hydroxyrisperidone by LC-MS/MS method and its clinical application [J]. Chin J Hosp Pharm (中国医院药学杂志), 2018, 38(10):1045-1050.
[25]	GUO Q H, REN F L. A simple and rapid LC-MS/MS method for the quantitative measurement of amisulpride, sulpiride, milnacipran, citalopram, venlafaxine and O-desmethyl venlafaxine serum concentration [J]. Chin J Hosp Pharm(中国医院药学杂志), 2019, 39(13):1347-1352.
[26]	HIEMKE C, BAUMANN P, BERGEMANN N, et al. Agnp consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011 [J]. Pharmacopsychiatry, 2011, 44(6):195-235.
[27]	DE CASTRO A, CONCHEIRO M, QUINTELA O, et al. LC-MS/MS method for the determination of nine antidepressants and some of their main metabolites in oral fluid and plasma. Study of correlation between venlafaxine concentrations in both matrices [J]. J Pharm Biomed Anal, 2008, 48(1):183-193.
[28]	PETRIDES A K, MOSKOWITZ J, JOHNSON-DAVIS K L, et al. The development and validation of a turbulent flow-liquid chromatography-tandem mass spectrometric method for the simultaneous quantification of citalopram, sertraline, bupropion and hydroxybupropion in serum [J]. Clin Biochem, 2014, 47(15):73-79.
[29]	DE SOUZA I D, DOMINGUES D S, QUEIROZ M E C. Hybrid silica monolith for microextraction by packed sorbent to determine drugs from plasma samples by liquid chromatography-tandem mass spectrometry [J]. Talanta, 2015, 140:166-175.
[30]	DOMINGUES D S, PINTO M A, DE SOUZA I D, et al. Determination of drugs in plasma samples by high-performance liquid chromatography-tandem mass spectrometry for therapeutic drug monitoring of schizophrenic patients [J]. J Anal Toxicol, 2016, 40(1):28-36.
[31]	PINTO M A L, DE SOUZA I D, QUEIROZ M E C. Determination of drugs in plasma samples by disposable pipette extraction with C18-BSA phase and liquid chromatography-tandem mass spectrometry [J]. J Pharm Biomed Anal, 2017, 139:116-124.
[32]	CHOONG E, RUDAZ S, KOTTELAT A, et al. Therapeutic drug monitoring of seven psychotropic drugs and four metabolites in human plasma by HPLC-MS[J]. J Pharm Biomed Anal, 2009, 50(5):1000-1008.
[33]	GOPINATH S, KUMAR R S, ALEXANDER S, et al. Development of a rapid and sensitive spe-lc-ms/ms method for the simultaneous estimation of fluoxetine and olanzapine in human plasma [J]. Biomed Chromatogr: BMC, 2012, 26(9):1077-1082.
[34]	YANG X, LI L, HE L J, et al. Determination of lamotrigine,olanzapine and quetiapine in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry and its application in therapeutic drug monitoring [J]. Chin Pharm J (中国药学杂志), 2020, 55(1):44-51.